Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans

Patrice Armstrong, Darshan S. Kelley, John W. Newman, Frank E. Staggers, Janna Hartiala, Hooman Allayee, Charles B. Stephensen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Arachidonate 5-lipoxygenase (ALOX5) gene variants that are common in people of African ancestry are associated with a differential cardiovascular disease (CVD) risk that may be ameliorated by intake of (n-3) PUFA, such as EPA or DHA. We conducted a double-masked, placebo (PL)-controlled trial of fish oil (FO) supplements to determine if changes in erythrocyte (n-3) PUFA composition, heart rate, blood pressure, and plasma lipid and lipoprotein concentrations are modified by genotype. Participants received 5 g/d FO (2 g EPA, 1 g DHA) or 5 g/d corn/soy oil (PL). A total of 116 healthy adults of African ancestry with selected genotypes (genotypes = "dd," "d5," and "55" with "d" representing the deletion of 1 or 2 Sp1 binding sites in the ALOX5 promoter and "5" indicating the common allele with 5 sites) were enrolled and 98 completed the study. FO caused significant increases (relative to PL) in erythrocyte EPA, DHA, and total (n-3) PUFA and a decrease in the (n-6) PUFA:(n-3) PUFA ratio in the low-CVD risk "d5" and "55" genotypes but not in the high-risk "dd" genotype. Similarly, HDL particle concentration decreased with FO relative to PL in the "d5" and "55" but not "dd" genotypes. The plasma TG concentration decreased significantly with FO relative to PL in the "d5" but not "dd" and "55" genotypes. No changes were seen in LDL particle or cholesterol concentrations, heart rate, or blood pressure. These findings indicate that the efficacy of FO supplements vary by ALOX5 genotype.

Original languageEnglish (US)
Pages (from-to)1417-1428
Number of pages12
JournalJournal of Nutrition
Volume142
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Arachidonate 5-Lipoxygenase
Fish Oils
African Americans
Genotype
Omega-3 Fatty Acids
Placebos
Genes
Cardiovascular Diseases
Erythrocytes
Heart Rate
Blood Pressure
Corn Oil
Lipoproteins
Alleles
Binding Sites
Cholesterol
Lipids

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Armstrong, P., Kelley, D. S., Newman, J. W., Staggers, F. E., Hartiala, J., Allayee, H., & Stephensen, C. B. (2012). Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. Journal of Nutrition, 142(8), 1417-1428. https://doi.org/10.3945/jn.112.159814

Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. / Armstrong, Patrice; Kelley, Darshan S.; Newman, John W.; Staggers, Frank E.; Hartiala, Janna; Allayee, Hooman; Stephensen, Charles B.

In: Journal of Nutrition, Vol. 142, No. 8, 08.2012, p. 1417-1428.

Research output: Contribution to journalArticle

Armstrong, P, Kelley, DS, Newman, JW, Staggers, FE, Hartiala, J, Allayee, H & Stephensen, CB 2012, 'Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans', Journal of Nutrition, vol. 142, no. 8, pp. 1417-1428. https://doi.org/10.3945/jn.112.159814
Armstrong, Patrice ; Kelley, Darshan S. ; Newman, John W. ; Staggers, Frank E. ; Hartiala, Janna ; Allayee, Hooman ; Stephensen, Charles B. / Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. In: Journal of Nutrition. 2012 ; Vol. 142, No. 8. pp. 1417-1428.
@article{f1715e269afa48a7bbf29c7a7c46ef33,
title = "Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans",
abstract = "Arachidonate 5-lipoxygenase (ALOX5) gene variants that are common in people of African ancestry are associated with a differential cardiovascular disease (CVD) risk that may be ameliorated by intake of (n-3) PUFA, such as EPA or DHA. We conducted a double-masked, placebo (PL)-controlled trial of fish oil (FO) supplements to determine if changes in erythrocyte (n-3) PUFA composition, heart rate, blood pressure, and plasma lipid and lipoprotein concentrations are modified by genotype. Participants received 5 g/d FO (2 g EPA, 1 g DHA) or 5 g/d corn/soy oil (PL). A total of 116 healthy adults of African ancestry with selected genotypes (genotypes = {"}dd,{"} {"}d5,{"} and {"}55{"} with {"}d{"} representing the deletion of 1 or 2 Sp1 binding sites in the ALOX5 promoter and {"}5{"} indicating the common allele with 5 sites) were enrolled and 98 completed the study. FO caused significant increases (relative to PL) in erythrocyte EPA, DHA, and total (n-3) PUFA and a decrease in the (n-6) PUFA:(n-3) PUFA ratio in the low-CVD risk {"}d5{"} and {"}55{"} genotypes but not in the high-risk {"}dd{"} genotype. Similarly, HDL particle concentration decreased with FO relative to PL in the {"}d5{"} and {"}55{"} but not {"}dd{"} genotypes. The plasma TG concentration decreased significantly with FO relative to PL in the {"}d5{"} but not {"}dd{"} and {"}55{"} genotypes. No changes were seen in LDL particle or cholesterol concentrations, heart rate, or blood pressure. These findings indicate that the efficacy of FO supplements vary by ALOX5 genotype.",
author = "Patrice Armstrong and Kelley, {Darshan S.} and Newman, {John W.} and Staggers, {Frank E.} and Janna Hartiala and Hooman Allayee and Stephensen, {Charles B.}",
year = "2012",
month = "8",
doi = "10.3945/jn.112.159814",
language = "English (US)",
volume = "142",
pages = "1417--1428",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "8",

}

TY - JOUR

T1 - Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans

AU - Armstrong, Patrice

AU - Kelley, Darshan S.

AU - Newman, John W.

AU - Staggers, Frank E.

AU - Hartiala, Janna

AU - Allayee, Hooman

AU - Stephensen, Charles B.

PY - 2012/8

Y1 - 2012/8

N2 - Arachidonate 5-lipoxygenase (ALOX5) gene variants that are common in people of African ancestry are associated with a differential cardiovascular disease (CVD) risk that may be ameliorated by intake of (n-3) PUFA, such as EPA or DHA. We conducted a double-masked, placebo (PL)-controlled trial of fish oil (FO) supplements to determine if changes in erythrocyte (n-3) PUFA composition, heart rate, blood pressure, and plasma lipid and lipoprotein concentrations are modified by genotype. Participants received 5 g/d FO (2 g EPA, 1 g DHA) or 5 g/d corn/soy oil (PL). A total of 116 healthy adults of African ancestry with selected genotypes (genotypes = "dd," "d5," and "55" with "d" representing the deletion of 1 or 2 Sp1 binding sites in the ALOX5 promoter and "5" indicating the common allele with 5 sites) were enrolled and 98 completed the study. FO caused significant increases (relative to PL) in erythrocyte EPA, DHA, and total (n-3) PUFA and a decrease in the (n-6) PUFA:(n-3) PUFA ratio in the low-CVD risk "d5" and "55" genotypes but not in the high-risk "dd" genotype. Similarly, HDL particle concentration decreased with FO relative to PL in the "d5" and "55" but not "dd" genotypes. The plasma TG concentration decreased significantly with FO relative to PL in the "d5" but not "dd" and "55" genotypes. No changes were seen in LDL particle or cholesterol concentrations, heart rate, or blood pressure. These findings indicate that the efficacy of FO supplements vary by ALOX5 genotype.

AB - Arachidonate 5-lipoxygenase (ALOX5) gene variants that are common in people of African ancestry are associated with a differential cardiovascular disease (CVD) risk that may be ameliorated by intake of (n-3) PUFA, such as EPA or DHA. We conducted a double-masked, placebo (PL)-controlled trial of fish oil (FO) supplements to determine if changes in erythrocyte (n-3) PUFA composition, heart rate, blood pressure, and plasma lipid and lipoprotein concentrations are modified by genotype. Participants received 5 g/d FO (2 g EPA, 1 g DHA) or 5 g/d corn/soy oil (PL). A total of 116 healthy adults of African ancestry with selected genotypes (genotypes = "dd," "d5," and "55" with "d" representing the deletion of 1 or 2 Sp1 binding sites in the ALOX5 promoter and "5" indicating the common allele with 5 sites) were enrolled and 98 completed the study. FO caused significant increases (relative to PL) in erythrocyte EPA, DHA, and total (n-3) PUFA and a decrease in the (n-6) PUFA:(n-3) PUFA ratio in the low-CVD risk "d5" and "55" genotypes but not in the high-risk "dd" genotype. Similarly, HDL particle concentration decreased with FO relative to PL in the "d5" and "55" but not "dd" genotypes. The plasma TG concentration decreased significantly with FO relative to PL in the "d5" but not "dd" and "55" genotypes. No changes were seen in LDL particle or cholesterol concentrations, heart rate, or blood pressure. These findings indicate that the efficacy of FO supplements vary by ALOX5 genotype.

UR - http://www.scopus.com/inward/record.url?scp=84866294913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866294913&partnerID=8YFLogxK

U2 - 10.3945/jn.112.159814

DO - 10.3945/jn.112.159814

M3 - Article

VL - 142

SP - 1417

EP - 1428

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 8

ER -